ICER evaluates drug price increases in California

ICER

20 October 2022 - Unsupported Price Increase” final report based on drugs identified through SB-17, the California drug price transparency law.

The ICER today posted a final report on unsupported price increases of prescription drugs in California during 2020. This California report used the same methodology for evaluating evidence as that used in ICER’s annual unsupported price increase report at the national level.

Read ICER announcement

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Review , Pricing , California